Spectral Medical Inc (TSE:EDT) Director Kevin Arnold Giese acquired 50,000 shares of Spectral Medical stock in a transaction dated Friday, February 14th. The shares were purchased at an average price of C$0.75 per share, with a total value of C$37,500.00. Following the acquisition, the director now owns 3,426,336 shares of the company’s stock, valued at C$2,569,752.
Shares of TSE:EDT opened at C$0.75 on Friday. Spectral Medical Inc has a 12-month low of C$0.30 and a 12-month high of C$0.85. The stock has a market cap of $155.81 million and a PE ratio of -57.69. The business has a 50 day moving average of C$0.75 and a 200-day moving average of C$0.55. The company has a quick ratio of 3.64, a current ratio of 4.24 and a debt-to-equity ratio of 21.26.
Spectral Medical (TSE:EDT) last issued its quarterly earnings data on Thursday, November 14th. The company reported C($0.01) earnings per share (EPS) for the quarter. The firm had revenue of C$0.53 million during the quarter. Equities research analysts expect that Spectral Medical Inc will post -0.06 earnings per share for the current year.
Spectral Medical Company Profile
Spectral Medical Inc focuses on the development and commercialization of treatment for septic shock in North America. The company markets Endotoxin Activity Assay, a rapid diagnostic test for the detection of components of gram negative bacterial cell wall in Europe and Canada; and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream in Europe, Canada, and Japan.
Further Reading: Dividend
Receive News & Ratings for Spectral Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Medical and related companies with MarketBeat.com's FREE daily email newsletter.